INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN11m ago
BL
Corporate insider

Burrows Scott L

Chief Financial OfficerCIK 0001853327

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 3
Max Insider Score27
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M—
15.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Chief Financial Officer · Jan 13, 2026
27
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL
$871K
10.0K sh
Jun 25, 2026
Jun 26, 2026
traded Jun 25, 2026
+1d
SEC FORM 4

Evidence

12
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise
M$218K
15.0K sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

23
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale
SELL$436K
5,000 sh
Jun 25, 2026Jun 26, 2026
traded Jun 25, 2026
+1dSEC FORM 4

Evidence

6
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$181K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

20
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$892K
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

0
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.5K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

9
BL
Burrows Scott LChief Financial Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence